EUVIMEDEUVIMED entdecken
Crossref

Considering biosimilar policy

Gilberto Castañeda-Hernández, Robert Strohal, João Gonçalves, Thomas Dörner, Valderilio Azevedo, John Isaacs, Iain McInnes

Considerations in Medicine · 2017

DOI: 10.1136/conmed-2017-100006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Considerations in Medicine, 2017. Verfasst von Gilberto Castañeda-Hernández und 6 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

With the authorisation of an increasing number of biosimilars, and the prospect of multiple biosimilar switching, biosimilar naming and the importance of this for pharmacovigilance are coming into sharper focus. Current naming policies are not universal; neither are extrapolation criteria. Indeed, consideration of whether we can extrapolate information from one indication or disease to another continues to be a divisive topic. However, this is changing, as we strive for a more harmonised approach. Such a unified approach will be needed when considering future strategies to follow for multiple biosimilar switching, especially so because there is currently no uniform policy regarding interchangeability, switching, and automatic substitution. In this multiple biosimilar setting, the question as to whether we can be confident to move across indications will be increasingly important. The cost of biosimilar switching also needs to be considered—biosimilar use may mean that patients need more training and medical visits, with associated administrative costs. The biosimilars debate seems to be refocusing issues that have previously been extensively discussed but that have recently lost impetus, including the role of clinical pharmacology in internal medicine.

Zitieren

APA

Castañeda-Hernández, G., Strohal, R., Gonçalves, J., Dörner, T., Azevedo, V., Isaacs, J., & McInnes, I. (2017). Considering biosimilar policy. Considerations in Medicine. https://doi.org/10.1136/conmed-2017-100006

Vancouver

Castañeda-Hernández G, Strohal R, Gonçalves J, Dörner T, Azevedo V, Isaacs J, et al. Considering biosimilar policy. Considerations in Medicine. 2017. doi:10.1136/conmed-2017-100006

BibTeX
@article{CastaedaHernndez2017,
  author = {Castañeda-Hernández, Gilberto and Strohal, Robert and Gonçalves, João and Dörner, Thomas and Azevedo, Valderilio and Isaacs, John and McInnes, Iain},
  title = {Considering biosimilar policy},
  journal = {Considerations in Medicine},
  year = {2017},
  doi = {10.1136/conmed-2017-100006}
}
Kostenlos starten →